Patent · US Active

Use of alkylphosphocholines in combination with antimetabolites for the treatment of benign and malignant oncoses in humans and mammals

US8383605B2 · kind B2 · utility

0Cited by

9References

9Claims

0Family size

Assignee

Aeterna Zentaris, Inc. · DE

Inventors

Jurgen Engel · Alzenau, DE
Eckhard Gunther · Offenbach, DE
Herbert Sindermann · Rodgau, DE
Babette Aicher · Frankfurt am Main, DE

Key dates

Filing date	Mar 31, 2010
Grant date	Feb 26, 2013
Priority date	—
Expiry date	Mar 31, 2030

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61P35/00
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The invention relates to the use of alkylphosphocholines in combination with antimetabolites for the treatment of multiple myeloma, colon cancer or renal cancer. Preferred alkylphosphocholines are described by the Formula II.A particularly effective treatment includes administering a combination of perifosine and capecitabine.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.